Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients? (Q46742608)

24 December 2017

title

Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients? (English)

1 reference

24 December 2017

0 references

1 reference

cytomegaloviral disease

1 reference

A Jain

1

1 reference

24 December 2017

M Orloff

2

1 reference

24 December 2017

R Kashyap

3

1 reference

24 December 2017

K Lansing

4

1 reference

24 December 2017

R Betts

5

1 reference

24 December 2017

R Mohanka

6

1 reference

24 December 2017

M Menegus

7

1 reference

24 December 2017

C Ryan

8

1 reference

24 December 2017

A Bozorgzadeh

9

1 reference

24 December 2017

language of work or name

English

0 references

publication date

1 September 2005

1 reference

24 December 2017

Transplantation Proceedings

published in

1 reference

24 December 2017

volume

37

1 reference

24 December 2017

issue

7

1 reference

24 December 2017

page(s)

3182-3186

1 reference

24 December 2017

CMV infection of transplant recipients

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2005.07.032

Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: a randomized, placebo-controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2005.07.032

Ganciclovir: an update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2005.07.032

Ganciclovir. An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2005.07.032

Prophylaxis of cytomegalovirus infection in liver transplantation: a randomized trial comparing a combination of ganciclovir and acyclovir to acyclovir. NIDDK Liver Transplantation Database

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2005.07.032

Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected].

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2005.07.032

High-dose acyclovir compared with short-course preemptive ganciclovir therapy to prevent cytomegalovirus disease in liver transplant recipients. A randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2005.07.032

Effect of oral acyclovir or ganciclovir therapy after preemptive intravenous ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus seropositive renal and liver transplant recipients receiving antilymphocyte antibody therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2005.07.032

Cytomegalovirus pp65 antigen-guided preemptive therapy with ganciclovir in solid organ transplant recipients: a prospective, double-blind, placebo-controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2005.07.032

Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2005.07.032

Cytomegalovirus disease following liver transplantation: an analysis of prophylaxis strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2005.07.032

Pharmacokinetics of valganciclovir and ganciclovir in renal impairment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2005.07.032

Prospective randomized trial to assess the value of preemptive oral therapy for CMV infection following liver transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2005.07.032

Pre-emptive oral ganciclovir can reduce the risk of cytomegalovirus disease in liver transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2005.07.032

Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositive volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2005.07.032

OKT3 treatment for allograft rejection is a risk factor for cytomegalovirus disease in liver transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2005.07.032

Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2005.07.032

10.1016/J.TRANSPROCEED.2005.07.032

7 January 2021

Identifiers

DOI

1 reference

24 December 2017

1 reference

24 December 2017